Astellas taps seasoned CMO amid shift to oncology; Doug Manion steps into a new Arena following $6.7B buyout
As Bernhardt Zeiher retires from Astellas’ chief medical officer position, the selection of his successor says a lot about the changes he’s seen at the company over his 12-year tenure.
Tadaaki Taniguchi, the new CMO, is a surgeon in oncology by training who’s led development for Merck, Bristol Myers Squibb and AstraZeneca in Japan before moving to the US, where he will be based. His most recent role at AstraZeneca was SVP, head of oncology business unit Asia strategy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.